SIRPant Immunotherapeutics jobs and careers

About SIRPant Immunotherapeutics

SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo. T cells are generated in vivo by administering proprietary activated autologous macrophages that activate tumoricidal T Cells, Neutrophils, and Natural Killer Cells whilst curtailing the activity of Tregs,MDSCs, IL-10 and TGFβ. T cells are generated ex vivo by the in vitro expansion of tumor-infiltrating T lymphocytes (TIL). Both in vivo and ex vivo methods result in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.

Founded in 2020 by Robert Towarnicki.